© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90743 refers to the Hepatitis B vaccine (HepB) specifically designed for adolescents, administered in a 2-dose schedule via intramuscular injection. Vaccines, unlike immune globulins that offer short-term, passive immunity, provide active and long-lasting immunity. This is achieved by introducing altered forms of specific viruses or bacteria into the recipient's immune system, prompting it to produce its own antibodies against these pathogens. The immune system retains the memory of how to generate these antibodies, ensuring protection against future exposures to the same antigens. The hepatitis B vaccine is crucial in preventing chronic liver disease, which can lead to severe health complications, including hospitalization and death. Additionally, it plays a significant role in reducing the risk of long-term consequences such as hepatocellular carcinoma, marking it as one of the pioneering cancer vaccines in clinical use. The vaccine can be derived from the blood plasma of asymptomatic carriers or produced through recombinant technology, where a plasmid containing the hepatitis gene is inserted into baker's yeast, followed by purification processes to isolate the yeast components. It is important to note that this code specifically reports the hepatitis B vaccine product for intramuscular use, while the actual injection procedure is reported separately. Other related codes include 90739 for adult dosages in a 2-dose or 4-dose schedule, 90740 for dialysis or immunosuppressed patients in a 3-dose schedule, 90744 for pediatric/adolescent dosages in a 3-dose schedule, and 90746 for adult 3-dose schedules, with 90747 covering dialysis or immunosuppressed patients in a 4-dose schedule.
© Copyright 2025 Coding Ahead. All rights reserved.
The Hepatitis B vaccine (CPT® Code 90743) is indicated for the prevention of hepatitis B virus infection in adolescents. This vaccine is particularly important for individuals who may be at risk of exposure to the virus, which can lead to chronic liver disease and its associated complications. The vaccine is recommended for adolescents as part of routine immunization schedules to ensure long-term protection against hepatitis B and its potential severe outcomes.
The administration of the Hepatitis B vaccine (CPT® Code 90743) follows a structured procedure to ensure effective immunization. The vaccine is delivered via intramuscular injection, typically into the deltoid muscle of the upper arm. The procedure begins with the healthcare provider verifying the patient's eligibility for the vaccine, including checking for any contraindications or previous allergic reactions to vaccine components. Following this, the provider prepares the vaccine by ensuring it is at the appropriate temperature and inspecting the vial for any particulate matter or discoloration. Once prepared, the provider cleans the injection site with an antiseptic wipe to minimize the risk of infection. The vaccine is then injected intramuscularly, and the provider may apply gentle pressure to the site afterward. After the injection, the patient is monitored for a brief period to observe for any immediate adverse reactions. Documentation of the vaccine administration, including the date, site, and any relevant patient information, is essential for maintaining accurate medical records.
After the administration of the Hepatitis B vaccine (CPT® Code 90743), patients are typically advised to remain in the healthcare setting for a short period to monitor for any immediate adverse reactions, such as allergic responses. Common post-procedure care includes advising the patient to apply a cool compress to the injection site if they experience soreness or swelling. Patients may also be informed about potential mild side effects, such as low-grade fever or fatigue, which usually resolve on their own within a few days. It is important for patients to complete the full vaccination series as recommended to ensure optimal immunity against hepatitis B. Follow-up appointments may be scheduled to administer the second dose of the vaccine, as part of the 2-dose schedule for adolescents. Additionally, patients should be encouraged to report any unusual or severe reactions to their healthcare provider promptly.
| Short Descr | HEPB VACC 2 DOSE ADOLESC IM | Medium Descr | HEPB VACCINE ADOLESCENT 2 DOSE SCHEDULE IM | Long Descr | Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use | Related Drugs | RECOMBIVAX HB | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Influenza, Pneumococcal Pneumonia, Hepatitis B, and Covid-19 Vaccines; Monoclonal Antibody Therapy Product | ASC Payment Indicator | Corneal tissue acquisition, hepatitis B vaccine; paid at reasonable cost. | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | O1G - Immunizations/Vaccinations | MUE | 1 | CCS Clinical Classification | 228 - Prophylactic vaccinations and inoculations |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | GA | Waiver of liability statement issued as required by payer policy, individual case | GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2016-01-01 | Changed | First appearance of change in codebook. |
| 2015-07-01 | Changed | Description Changed |
| 2011-01-01 | Changed | Short description changed. |
| 2001-01-01 | Added | First appearance in code book in 2001. |
Get instant expert-level medical coding assistance.